Non-small Cell Lung Cancer Registry

Inclusion Criteria: * Age greater than or equal to 18 years * Histologically confirmed NSCLC (squamous cell carcinoma, adenocarcinoma, large cell carcinoma). * Unresectable Stage IIIB with pleural effusion or stage IV NSCLC * ECOG performance status of 0 or 1 Exclusion Criteria: * Patients who received an IV bisphosphonate (e.g.pamidronate; zoledronic acid) * Patients who received an oral bisphosphonate therapy in the 6 months prior to screening (alendronate; etidronate; risedronate; tiludronate; ibandronate) * Patients who are currently receiving any investigational drugs that are suspected to have renal toxicity and/or are excreted by the kidneys * Known clinically significant hypersensitivity to zoledronic acid or other bisphosphonates or any of the excipients in the formulation of zoledronic acid (mannitol, sodium citrate) * Abnormal renal function or creatinine clearance * Unstable brain metastasis * Women of childbearing potential not using a medically recognized form of contraception, as well as women who are breastfeeding * Patients with nonmalignant conditions which would confound the evaluation of the primary endpoint, impair tolerance of therapy, or prevent compliance to the protocol